Mircera market seen growing to $3.69 million by 2030
The global Mircera market is projected to rise from $2.84 million in 2025 to $3.69 million by 2030, driven by chronic kidney disease growth, more dialysis patients and demand for less frequent anemia treatment. North America held the largest share in 2025, while long-acting ESAs and extended dosing intervals are expected to shape future demand.
Why it matters: - The Mircera market is tied to anemia care in chronic kidney disease, a condition affecting a growing patient base worldwide. - Rising demand for therapies that reduce injection frequency could support broader use of long-acting erythropoiesis-stimulating agents. - The forecast points to continued expansion in dialysis-linked treatment demand and specialty nephrology care.
What happened: - The Business Research Company projected the Mircera market will rise from $2.84 million in 2025 to $3 million in 2026. - The report forecasts the market will reach $3.69 million by 2030. - The company said the market is expected to grow at a CAGR of 5.7% from 2025 to 2026 and 5.3% through 2030. - North America held the largest share of the Mircera market in 2025. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.
The details: - Mircera is a long-acting erythropoiesis-stimulating agent used to treat anemia linked to chronic kidney disease. - The drug is given by intravenous or subcutaneous injection. - Its dosing schedule is typically once every two to four weeks. - Historical growth was linked to higher CKD prevalence, limits of short-acting ESAs, clinical validation of continuous erythropoietin receptor activators, expansion of dialysis infrastructure and better anemia management protocols. - Future growth is expected to come from an aging population, more dialysis patients, demand for therapies with fewer injections, expansion of specialty nephrology clinics and higher healthcare spending on CKD. - The report flagged greater use of long-acting ESAs, preference for extended dosing intervals, a larger CKD patient base, more treatment in dialysis centers and a focus on stable hemoglobin management as key trends. - CKD is a progressive condition marked by gradual loss of kidney function and is often linked to diabetes and hypertension. - Anemia is a common CKD complication because the kidneys produce less erythropoietin. - A Kidney Research UK report from June 2023 said about 7.2 million people in the UK live with CKD, or more than 10% of the population. - That UK figure is expected to rise to 7.61 million by 2033. - The report says its 2026 edition includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and key technology and future trend analysis. - The company also listed sample and full-report links: Download a free sample of the Mircera market report and View the full Mircera market report.
Between the lines: - The market outlook reflects a treatment category shaped less by short-term drug innovation and more by chronic disease prevalence, delivery convenience and dialysis system growth. - The emphasis on longer dosing intervals suggests convenience and adherence remain important buying factors in anemia management. - North America’s lead in 2025 likely reflects established CKD treatment infrastructure and broader use of specialty therapies.
What's next: - Market growth will likely track CKD prevalence, dialysis utilization and healthcare spending over the next several years. - The report suggests adoption will continue shifting toward long-acting ESAs and less frequent administration schedules. - Additional regional growth will depend on how quickly nephrology infrastructure expands outside North America.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
UK Post Observer
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.